GILD logo

Gilead Sciences Inc. (GILD)

$170.26

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on GILD

Market cap

$211.18B

EPS

-3.15

P/E ratio

--

Price to sales

6.15

Dividend yield

1.926%

Beta

0.349701

Price on GILD

Previous close

$167.58

Today's open

$166.12

Day's range

$165.72 - $171.36

52 week range

$116.88 - $176.58

Profile about GILD

CEO

Daniel P. O¿Day

Employees

17000

Headquarters

Foster City, CA

Exchange

Nasdaq Global Select

Shares outstanding

1.24B

Issue type

Common Stock

GILD industries and sectors

Healthcare

Pharmaceuticals

News on GILD

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

news source

Zacks Investment Research • 10 hours ago

news preview

Worried investors are paying up for these stocks — some with up to 49% upside, analysts say

Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.

news source

Market Watch • 9 hours ago

news preview

Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind

Gilead Sciences NASDAQ: GILD expects its expanding HIV prevention portfolio and a potential new cell therapy for multiple myeloma to support growth, even as a negotiated price change for its HIV treatment Biktarvy creates an anticipated $1.5 billion headwind in 2028, Chief Financial Officer Andy Dickinson said at an investor conference.

news source

MarketBeat • Nov 17, 2026

news preview

Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs

Gilead Sciences NASDAQ: GILD expects HIV and oncology to drive growth through the rest of the decade while it builds an inflammation business for the 2030s, executives said at a London healthcare conference.

news source

MarketBeat • Nov 17, 2026

news preview

Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript

Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Gilead Sciences, Inc. (GILD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Gilead Sciences, Inc. (GILD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting

FOSTER CITY, Calif.--(BUSINESS WIRE)--Suffolk, one of the most innovative and successful builders in the country, recently joined Gilead Sciences to celebrate the completion of its new Research Center in Foster City, California. Through close collaboration with Gilead, Suffolk delivered a highly specialized and adaptable research environment designed to evolve alongside the company's scientific needs, creating laboratory spaces that can accommodate new research teams, equipment and technologies.

news source

Business Wire • Nov 17, 2026

news preview

Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease (BVD). The agreements cover 127 primarily low- and lower-middle-income countries, consistent with the geographic scope of Gilead's existing voluntary licensing ag.

news source

Business Wire • Nov 16, 2026

news preview

Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?

GILD's HIV franchise gains momentum as Yeztugo sales surge, Biktarvy maintains market leadership and an expanding pipeline strengthens long-term growth prospects.

news source

Zacks Investment Research • Nov 12, 2026

news preview

3 Pharmaceutical Stocks That Offer Safety and Growth

Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI stocks, have driven strong portfolio gains for active and passive investors.

news source

MarketBeat • Nov 12, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Gilead Sciences Inc.

Open an M1 investment account to buy and sell Gilead Sciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in GILD on M1